WW 3Q 2026: Revenue $152.9M, EPS $1.51 — 10-Q Summary

WW International reported 3Q 2026 revenue of $152.9M, down 11.2% YoY, but swung to a net income of $15.11M. Behavioral subscriber decline drove revenue drop, while Clinical subscribers grew. EPS was $1.51. Lower marketing and admin expenses improved profitability.

Original reporting
Published Nov 5, 2026, 12:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 12:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
WW 3Q 2026: Revenue $152.9M, EPS $1.51 — 10-Q Summary — source image
Decision brief

The 30-second read

$WWBearishMed
01

Why it matters

The earnings miss may trigger a short‑term sell‑off, but cost cuts and clinical growth provide a potential upside narrative.

02

Market read

The earnings release provides fresh data that could influence WW's stock price and sector peers.

03

What to watch

Cost reductions in marketing and SG&A may improve margins, and the rebound in clinical growth could accelerate in upcoming quarters.

Relevance 7/10Novelty 8/10Timing: post‑market today

Background

WW International (ticker WW) filed its Q3 2026 Form 10‑Q, showing an 11.2% revenue decline and a swing to net income.

Company-level read

Ticker impact

$WWBearishHigh confidence
Context

Q3 2026 revenue $152.9M and EPS $1.51 reported in WW International's 10‑Q filing.

Expected impact

likely downward pressure as the market prices in the revenue decline and modest earnings beat.

Evidence & confidence

The earnings miss on revenue and modest profit suggest limited upside; investors may sell on the surprise.

Market effects

Weight‑loss and wellness sector may see modest re‑rating as subscriber mix shifts toward higher‑margin clinical services.

U.S. consumer discretionary sentiment could soften slightly.

Limited; impact confined to WW and its niche peers.

Counterpoint

The shift to higher‑margin clinical subscribers could drive future profitability despite short‑term revenue dip.

Key entities

  • WW International, Inc.

    Provider of weight‑loss and wellness programs, listed on NYSE under ticker WW.

Related articles

$WWMedAI 8/10

What WW International (WW) Said on Its Q3 Earnings Call

WW International reported Q3 earnings, highlighting a 40% YoY increase in clinical subscribers to 174,000, though down from 197,000 in Q2. Behavioral subscription revenue fell 22% to $113.9M, while clinical revenue rose 48% to $38M. Adjusted gross margin reached 74.6%, and marketing expenses declined. The company narrowed its 2026 revenue guidance to $625M-$630M and adjusted EBITDA to $110M-$115M. Cash increased to $126.4M, and debt was reduced by 70%.

$WWMedAI 8/10

WW International Inc (WW) (Q3 2026) Earnings Call Highlights: Clinical Revenue Surges 48%

WW International reported Q3 2026 revenue of $152.9M, down 11% YoY, with behavioral subscription revenue dropping 22%. Clinical revenue surged 48%, but clinical subscribers declined sequentially. Full-year revenue guidance was narrowed to $625-$630M. Core+ subscribers grew 16% YoY, driven by GLP-1 program adoption and virtual experiences. The company expects flat gross margins at ~74% despite clinical mix growth.

$WWMed

WW International, Inc. Q3 2026 Earnings Call Summary

WW International reported Q3 2026 earnings, highlighting a strategic shift to higher-value tiers (Core+ and Med+) generating 50% of revenue. Clinical revenue grew 48% YoY, driven by Med+ and GLP-1 Success Program. Core+ saw subscriber growth for four consecutive quarters. The company expects sustainable growth in 2027, with clinical revenues projected to reach 25% of total revenue. Debt reduced by 70% since 2025, and net income turned positive.

$WWHigh

Why is WW International stock rallying today?

WW International's stock rose 8.6% after Northland Securities initiated coverage with an Outperform rating and $25.00 price target, citing partnerships and long-term recovery potential. Institutional investors increased positions, and the broader market's tech growth theme supported the rally.